Boothbay Fund Management’s NovoCure NVCR Stock Holding History

Boothbay Fund Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-82,412	Closed	-$898K	–	2514
2026 Q1	$898K	Buy	82,412 +31,870	+63%	+$398K	0.01%	1004
2025 Q4	$654K	Buy	+50,542	New	+$649K	0.01%	999
2023 Q2	–	Sell	-35,600	Closed	-$2.14M	–	2138
2023 Q1	$2.14M	Buy	+35,600	New	+$2.84M	0.04%	626

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Boothbay Fund Management's NVCR Position: Q2 2026 in Review

Boothbay Fund Management sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 82,412 shares — an estimated $898K sold.

Boothbay Fund Management first reported a position in NVCR in Q1 2023 and held it in 3 quarters. The position peaked at $2.14M in Q1 2023. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Boothbay Fund Management reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 82,412 NovoCure shares in Q2 2026, an estimated $898K.
Boothbay Fund Management first reported a position in NovoCure in Q1 2023 and held it in 3 quarters.
Boothbay Fund Management's NovoCure position peaked at $2.14M in Q1 2023.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.